Volume 20 Number 2
Spring 2020
Myeloma Today A publication of the International Myeloma Foundation
A Message from the IMF President & CEO
In this edition: } Immunotherapy in Myeloma: } FDA Approves Isatuximab Attacking the Plasma Cell in New Ways PAGE 4
(SarclisaÂŽ) for Relapsed Refractory Myeloma PAGE 6
This edition of Myeloma Today is supported by Amgen ⢠Genentech ⢠Sanofi Genzyme ⢠Takeda Oncology